UTP6 Antibody

What is UTP6 and what cellular functions does it participate in?

UTP6 (also known as HCA66) is a small subunit processome component homolog involved in ribosome biogenesis, specifically in the processing of 18S rRNA. The protein consists of 597 amino acids with a molecular weight of approximately 70 kDa . Recent research has revealed that UTP6 may play significant roles beyond ribosome biogenesis, particularly in cancer biology. Studies have demonstrated that UTP6 expression levels correlate with chemoradiotherapy resistance in colorectal cancer, suggesting its involvement in regulatory pathways that influence treatment outcomes . Additionally, UTP6 appears to interact with transcription factor pathways, potentially regulating FOXK2 expression, which has implications for cell proliferation and cancer progression .

What types of UTP6 antibodies are available for research applications?

Multiple types of UTP6 antibodies are available, varying in their target epitopes, host species, and applications:

Selection should be based on the specific experimental requirements, including the detection method, sample type, and research question being addressed.

What species reactivity can I expect from commonly available UTP6 antibodies?

Most commercially available UTP6 antibodies exhibit reactivity with human samples, while some also recognize mouse and rat UTP6 proteins . The broader reactivity profile includes:

When working with non-human samples, it is advisable to verify sequence homology in the epitope region or conduct preliminary validation experiments to confirm cross-reactivity.

What are the optimal conditions for Western blot detection of UTP6?

For optimal Western blot detection of UTP6, consider the following protocol guidelines:

• Sample preparation: Lyse cells or tissues in RIPA buffer containing protease inhibitors.

• Protein separation: Use 8-10% SDS-PAGE gels due to UTP6's size (70 kDa).

• Transfer: Semi-dry or wet transfer to PVDF membrane at 100V for 60-90 minutes.

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: UTP6 antibody dilution ranges from 1:200 to 1:1000 in blocking buffer, with overnight incubation at 4°C .

• Detection: HRP-conjugated secondary antibody at 1:5000-1:10000 dilution.

The observed molecular weight should be approximately 70 kDa, consistent with the calculated molecular weight based on the 597 amino acid sequence . Positive controls that have been verified to express detectable levels of UTP6 include HeLa cells and HEK-293 cells . When troubleshooting, consider that the protein expression level may vary significantly between tissue types, with notable expression in proliferating cells and cancer cell lines.

How can I optimize immunohistochemical detection of UTP6 in tissue samples?

For successful immunohistochemical detection of UTP6 in tissue samples, follow these methodological guidelines:

• Tissue preparation: Fix tissues in 10% neutral buffered formalin, embed in paraffin, and section at 4-6 μm thickness.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) for 15-20 minutes is recommended.

• Blocking: 3% hydrogen peroxide followed by 5-10% normal serum blocking.

• Primary antibody: Select antibodies specifically validated for IHC applications, such as those targeting the center region or C-terminal (AA 565-597) of UTP6 .

• Detection system: Use streptavidin-biotin complex method as employed in published studies .

• Scoring: Implement semi-quantitative analysis with random field selection in multiple directions (up, center, down, left, and right) under high magnification .

In colorectal cancer studies, researchers have successfully used this approach to correlate UTP6 expression with clinical outcomes, demonstrating that the protein can be reliably detected in paraffin-embedded clinical specimens .

What controls should be included when validating a new lot of UTP6 antibody?

Comprehensive validation of a new UTP6 antibody lot should include:

• Positive controls:

  • Cell lines with confirmed UTP6 expression (HeLa, HEK-293)

  • Tissue samples known to express UTP6 (colorectal cancer tissues with varied expression levels)

• Negative controls:

  • Primary antibody omission

  • Isotype control (rabbit IgG at matching concentration)

  • Phosphate-buffered saline (PBS) as used in published studies

• Specificity controls:

  • Pre-absorption with immunizing peptide

  • siRNA/shRNA knockdown of UTP6 in positive control cells

  • Comparison with a second antibody targeting a different epitope of UTP6

• Cross-reactivity assessment:

  • Testing across multiple species if cross-species reactivity is claimed

  • Verify signal at the expected molecular weight (70 kDa)

Document lot-to-lot variability by comparing staining intensity and pattern with previously validated lots on the same samples.

How can UTP6 antibodies be used to investigate its role in cancer therapeutic resistance?

UTP6 antibodies can be instrumental in studying cancer therapeutic resistance through multiple methodological approaches:

• Expression correlation studies:

  • Use immunohistochemistry with UTP6 antibodies on pre- and post-treatment tumor samples to correlate expression levels with treatment response .

  • Implement semi-quantitative scoring systems to stratify patients based on UTP6 expression levels.

• Mechanistic investigations:

  • Combine UTP6 immunoprecipitation (using IP-validated antibodies) with mass spectrometry to identify interaction partners in resistant versus sensitive cells .

  • Perform ChIP-seq experiments using UTP6 and FOXK2 antibodies to explore the regulatory relationship between these proteins in the context of treatment resistance .

• Prognostic assessment:

  • Conduct tissue microarray analyses of large patient cohorts to evaluate UTP6 as a biomarker for treatment response prediction.

  • Correlate UTP6 expression with survival outcomes (DFS, OS) and therapeutic resistance markers.

Published studies have demonstrated that low UTP6 expression was significantly associated with chemoradiotherapy resistance in rectal cancer patients (p = 0.02, AUC = 0.76) . Furthermore, UTP6 expression showed significant correlation with tumor regression grade (TRG) (r = -0.35, p = 0.02), suggesting its potential utility as a predictive biomarker for treatment response .

What are the technical challenges in detecting low levels of UTP6 protein in clinical samples?

Detecting low levels of UTP6 protein in clinical samples presents several technical challenges that require methodological adaptations:

• Signal amplification strategies:

  • Implement tyramide signal amplification (TSA) for immunohistochemistry

  • Use high-sensitivity chemiluminescent substrates for Western blot

  • Consider multiplexed detection systems to normalize against housekeeping proteins

• Sample preparation optimization:

  • Enrich for nuclear fractions where UTP6 is predominantly localized

  • Optimize antigen retrieval conditions (extended heat-induced epitope retrieval)

  • Use fresh frozen samples when possible to minimize epitope degradation

• Antibody selection considerations:

  • Choose antibodies with demonstrated sensitivity in the low nanogram range

  • Consider using antibodies targeting different epitopes in parallel to confirm results

  • Validate detection limits using recombinant UTP6 protein standards

• Quantification approaches:

  • Implement digital image analysis with background subtraction

  • Use calibrated standards for Western blot quantification

  • Consider more sensitive detection methods like proximity ligation assay (PLA)

In published studies, researchers successfully detected varying levels of UTP6 expression in colorectal cancer samples, enabling stratification of patients into high and low expression groups with significant prognostic differences . This suggests that current methodologies can detect clinically relevant expression differences when properly optimized.

How does UTP6 antibody specificity influence the interpretation of its proposed role in regulating FOXK2 expression?

• Epitope considerations:

  • Antibodies targeting different domains of UTP6 may yield varying results if certain epitopes are masked during specific protein-protein interactions.

  • The accessibility of epitopes may differ between subcellular compartments, potentially affecting detection of UTP6-FOXK2 interactions in nuclear versus cytoplasmic fractions.

• Validation requirements for interaction studies:

  • When performing co-immunoprecipitation of UTP6 and FOXK2, antibody specificity should be validated using reciprocal IP approaches.

  • Orthogonal methods (e.g., proximity ligation assay, FRET) should be employed to confirm direct interactions detected using antibody-based methods.

• Technical controls for regulatory relationship studies:

  • siRNA knockdown of UTP6 followed by FOXK2 immunoblotting provides more reliable evidence than correlative expression data alone.

  • ChIP experiments investigating UTP6 regulation of FOXK2 require stringent controls to rule out non-specific DNA binding.

• Methodological approaches for confirming regulatory mechanisms:

  • Use multiple antibodies targeting different UTP6 epitopes to confirm consistent effects on FOXK2 expression.

  • Implement rescue experiments with exogenous UTP6 expression to verify the specificity of observed FOXK2 regulatory effects.

What are common causes of false positive or negative results when using UTP6 antibodies?

Common causes of false results when using UTP6 antibodies include:

UTP6 detection can be particularly challenging due to its nuclear localization and involvement in large protein complexes, which may restrict epitope accessibility . In clinical samples, variations in fixation protocols can significantly impact detection efficiency.

How should researchers validate UTP6 antibody performance across different experimental systems?

A comprehensive validation strategy for UTP6 antibodies across different experimental systems should include:

• Expression system validation:

  • Test antibody performance in recombinant expression systems (e.g., transfected cells overexpressing UTP6)

  • Verify specificity using genetic knockout or knockdown approaches

  • Compare reactivity with endogenous UTP6 across multiple cell lines

• Application-specific validation:

  • For WB: Confirm band specificity at expected molecular weight (70 kDa) and optimize antibody dilution (1:200-1:1000)

  • For IHC: Validate on known positive tissues with appropriate negative controls

  • For IP: Verify precipitation efficiency and specificity using Western blot detection

  • For ICC/IF: Confirm expected subcellular localization pattern

• Cross-species validation:

  • Examine sequence homology in the epitope region across target species

  • Test antibody on samples from multiple species under identical conditions

  • Validate using species-specific positive and negative controls

• Lot-to-lot consistency assessment:

  • Maintain reference samples for comparison across antibody lots

  • Document key performance metrics (signal intensity, background, etc.)

  • Establish internal quality control standards for acceptance criteria

These validation steps are essential since published research on UTP6's role in cancer relies heavily on accurate detection and quantification of its expression levels .

What strategies can improve reproducibility when quantifying UTP6 expression in tissue microarrays?

To enhance reproducibility when quantifying UTP6 expression in tissue microarrays (TMAs), researchers should implement these strategies:

• Standardized staining protocols:

  • Use automated immunostaining platforms to minimize technical variation

  • Process all TMA sections in a single batch when possible

  • Include reference control tissues on each TMA slide

• Robust scoring methodologies:

  • Implement semi-quantitative scoring as demonstrated in published UTP6 research

  • Use random field selection in multiple directions (up, center, down, left, right)

  • Employ at least two independent scorers blinded to clinical outcomes

  • Calculate inter-observer agreement statistics (kappa values)

• Digital pathology approaches:

  • Use digital image analysis software with validated algorithms for nuclear protein detection

  • Calibrate analysis parameters using control samples with known UTP6 expression levels

  • Document all image acquisition settings and analysis parameters for reproducibility

• Statistical considerations:

  • Establish predefined cutoff values for categorizing UTP6 expression levels

  • Use continuous measurements where possible to avoid arbitrary dichotomization

  • Apply appropriate statistical methods for multiple comparisons and batch effects correction

In published UTP6 research, investigators successfully used immunohistochemical analysis of UTP6 expression in 125 locally advanced rectal cancer patient samples to establish significant associations with survival outcomes . This demonstrates that with proper methodology, quantitative assessment of UTP6 expression can yield clinically meaningful and reproducible results.

How can UTP6 antibodies be utilized in studying the relationship between ribosome biogenesis and cancer therapeutic response?

UTP6 antibodies provide valuable tools for investigating the emerging connection between ribosome biogenesis and cancer therapeutic response:

• Mechanistic studies of the UTP6-ribosome-cancer axis:

  • Use immunofluorescence co-localization studies with UTP6 antibodies and ribosomal markers to track changes in ribosome biogenesis following therapy.

  • Employ chromatin immunoprecipitation with UTP6 antibodies to identify binding to ribosomal DNA and potential transcriptional regulatory roles.

  • Perform immunoprecipitation followed by mass spectrometry to map the UTP6 interactome in sensitive versus resistant cancer cells.

• Translational research applications:

  • Develop immunohistochemical scoring algorithms for UTP6 expression in pre-treatment biopsies to predict therapeutic response.

  • Monitor dynamic changes in UTP6 expression during treatment using serial biopsies or liquid biopsy approaches.

  • Investigate UTP6 in combination with other ribosome biogenesis markers to create more robust predictive signatures.

• Therapeutic targeting strategies:

  • Use UTP6 antibodies to validate knockdown efficiency in preclinical models targeting the ribosome biogenesis pathway.

  • Screen for compounds that modulate UTP6 expression or function and assess their potential to overcome therapeutic resistance.

Current research has established that low UTP6 expression correlates significantly with chemoradiotherapy resistance in colorectal cancer . This suggests that UTP6 may serve as a critical link between ribosome biogenesis dysfunction and treatment response, potentially through mechanisms involving FOXK2 regulation .

What techniques can combine UTP6 antibody detection with transcriptomic data to understand its regulatory networks?

Integrative approaches combining UTP6 antibody detection with transcriptomic data can reveal complex regulatory networks:

• Multi-omics correlation methodologies:

  • Correlate UTP6 protein levels (detected by quantitative immunohistochemistry) with RNA-seq data from matched samples.

  • Implement weighted gene co-expression network analysis (WGCNA) to identify gene modules associated with varying UTP6 expression levels .

  • Apply gene set enrichment analysis (GSEA) to identify pathways enriched in samples with differential UTP6 expression .

• Mechanistic validation techniques:

  • Perform ChIP-seq using UTP6 antibodies followed by integration with RNA-seq data to identify direct transcriptional targets.

  • Use RIP-seq (RNA immunoprecipitation sequencing) with UTP6 antibodies to identify RNA binding partners and potential post-transcriptional regulatory roles.

  • Implement ATAC-seq in cellular models with modulated UTP6 expression to assess changes in chromatin accessibility.

• Visualization and analysis frameworks:

  • Create correlation networks visualizing genes whose expression correlates with UTP6 protein levels.

  • Apply machine learning approaches to identify gene signatures that predict UTP6 protein expression.

  • Develop computational models integrating protein-level and transcript-level data to predict regulatory relationships.

Published research has successfully used WGCNA to demonstrate that UTP6 expression is associated with chemoradiotherapy resistance modules enriched for translation, DNA replication, and androgen receptor signaling pathways . Gene set enrichment and co-expression analyses have further suggested that UTP6 may regulate FOXK2 expression through transcription factor pathways .

What considerations are important when using UTP6 antibodies in multiplex immunofluorescence studies?

When incorporating UTP6 antibodies into multiplex immunofluorescence studies, several technical considerations are crucial:

• Antibody compatibility assessment:

  • Verify species compatibility among primary antibodies to avoid cross-reactivity.

  • Test each UTP6 antibody individually before combining with other antibodies.

  • Consider using UTP6 antibodies from different species than other target antibodies.

  • Validate that UTP6 antibody performance is not affected by multiplexing conditions.

• Signal optimization strategies:

  • Determine the optimal sequence of antibody application, as UTP6 detection may require primary position in the sequence.

  • Carefully titrate each antibody to achieve balanced signal intensity across all targets.

  • Select fluorophores with appropriate spectral separation, considering UTP6's predominantly nuclear localization.

  • Implement appropriate controls for autofluorescence and spectral bleed-through.

• Technical workflow considerations:

  • For sequential multiplexing: Validate complete stripping/denaturation of UTP6 antibodies between rounds.

  • For simultaneous multiplexing: Ensure antibody pairs are tested for cross-talk and interference.

  • Include single-color controls for each antibody, including UTP6.

  • Document the specific UTP6 antibody clone/catalog number and concentration used.

• Analysis approaches:

  • Develop cell segmentation algorithms appropriate for nuclear proteins like UTP6.

  • Implement colocalization analysis methods to study UTP6 interactions with other proteins.

  • Use quantitative approaches that account for differential subcellular localization.